文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

巴辛烯酮联合达格列净与达格列净单药治疗慢性肾脏病伴白蛋白尿患者的比较:一项随机、活性对照、双盲、2b期临床试验

Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
PubMed 文献 · Lancet · 2025-11-08

MIRO-CKD是一项在15个国家106个临床中心开展的多中心、随机、双盲、活性对照、剂量探索2b期试验,纳入324例eGFR 25-<60 mL/min/1.73 m²且UACR >100-≤5000 mg/g的慢性肾脏病患者。第12周时,巴辛烯酮15 mg联合达格列净10 mg组和巴辛烯酮40 mg联合达格列净10 mg组的UACR较达格列净10 mg联合安慰剂组分别降低22.8%(90% CI -33.3至-10.7;p=0.0038)和32.8%(90% CI -42.0至-22.1;p<0.0001)。联合治疗耐受性良好,高钾血症不良事件发生率分别为6%、7%和5%。

要点

  • 巴辛烯酮15 mg联合达格列净10 mg组第12周UACR较达格列净10 mg联合安慰剂组降低22.8%(90% CI -33.3至-10.7;p=0.0038)。
  • 巴辛烯酮40 mg联合达格列净10 mg组第12周UACR较达格列净10 mg联合安慰剂组降低32.8%(90% CI -42.0至-22.1;p<0.0001)。
  • 研究者报告的高钾血症不良事件发生率:巴辛烯酮15 mg联合组6%(7/108)、巴辛烯酮40 mg联合组7%(8/110)、达格列净联合安慰剂组5%(5/106)。

核心结论

  • 在疾病进展风险增加的慢性肾脏病患者中,巴辛烯酮联合达格列净固定剂量组合在降低白蛋白尿方面优于达格列净单药。
  • 巴辛烯酮联合达格列净耐受性良好,对钾的影响轻微,未发现非预期安全性问题。

研究设计与样本

  • MIRO-CKD为多中心、随机、双盲、活性对照、剂量探索2b期试验,在美洲、亚洲和欧洲15个国家的106个临床实践中心开展。
  • 纳入标准为eGFR 25-<60 mL/min per 1.73 m²、UACR >100-≤5000 mg/g、血清钾3.5-5.0 mmol/L的成人患者。
  • 324例参与者按1:1:1随机分配至巴辛烯酮15 mg联合达格列净10 mg组(n=108)、巴辛烯酮40 mg联合达格列净10 mg组(n=110)或达格列净10 mg联合安慰剂组(n=106),每日一次,在耐受情况下作为肾素-血管紧张素系统抑制剂的辅助治疗,治疗12周后接8周洗脱期。
  • 主要疗效终点为基线至第12周UACR的相对变化,在所有随机分配且至少接受一剂研究药物的参与者中分析,缺失值未填补,假设缺失UACR值为随机缺失。

主要发现

  • 参与者平均年龄64.6岁(SD 12.4),平均eGFR 42.2 mL/min per 1.73 m²(SD 10.5),中位UACR 365 mg/g(IQR 157至825),56%正在使用SGLT2抑制剂。
  • 110例(34%)为女性,214例(66%)为男性;103例(32%)为亚洲人,23例(7%)为黑人或非裔美国人,183例(56%)为白人。
  • 第12周时,巴辛烯酮15 mg联合达格列净10 mg组UACR较达格列净10 mg联合安慰剂组的差异为-22.8%(90% CI -33.3至-10.7;p=0.0038)。
  • 第12周时,巴辛烯酮40 mg联合达格列净10 mg组UACR较达格列净10 mg联合安慰剂组的差异为-32.8%(90% CI -42.0至-22.1;p<0.0001)。
  • 研究者报告的高钾血症不良事件发生率:巴辛烯酮15 mg联合达格列净10 mg组6%(7/108),巴辛烯酮40 mg联合达格列净10 mg组7%(8/110),达格列净10 mg联合安慰剂组5%(5/106)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce albuminuria and risk of progression of chronic kidney disease. Non-steroidal mineralocorticoid receptor antagonists (MRA) have similar effects in patients with type 2 diabetes with chronic kidney disease. We aimed to assess efficacy and safety of the novel MRA balcinrenone combined with the SGLT2 inhibitor dapagliflozin in a randomised controlled trial. METHODS: MIRO-CKD was a multicentre, randomised, double-blind, active controlled, dose-finding phase 2b trial conducted in 106 clinical practice sites in 15 countries in America, Asia, and Europe. Adults with estimated glomerular filtration rate (eGFR) of 25-<60 mL/min per 1·73 m2, a urine albumin-to-creatinine ratio (UACR) of >100-≤5000 mg/g, and a serum potassium concentration 3·5-5·0 mmol/L were randomly assigned (1:1:1) via an interactive response technology system to treatment with combined balcinrenone 15 mg plus dapagliflozin 10 mg, balcinrenone 40 mg plus dapagliflozin 10 mg, or dapagliflozin 10 mg plus placebo (double-dummy technique) once daily as adjunct to renin angiotensin system inhibitors, if tolerated, for 12 weeks, followed by an 8-week wash-out period. The primary efficacy endpoint was relative change in UACR from baseline to week 12, analysed in all participants who were randomly assigned and received at least one dose of study drug. Missing values were not imputed, assuming that any missing UACR values were missing at random. Other endpoints included safety and tolerability. The MIRO-CKD trial was registered at ClinicalTrials.gov, NCT06350123, and is completed. FINDINGS: Between May 1 and Dec 18, 2024, 613 participants were assessed for eligibility, 289 were excluded due to not meeting eligibility criteria or withdrawing, and 324 were randomly assigned to receive balcinrenone 15 mg plus dapagliflozin 10 mg (n=108), balcinrenone 40 mg plus dapagliflozin 10 mg (n=110), or dapagliflozin plus placebo (n=106). Participants had a mean age of 64·6 years (SD 12·4), a mean eGFR of 42·2 mL/min per 1·73 m2 (SD 10·5), median UACR of 365 mg/g (IQR 157 to 825), and 56% were taking SGLT2 inhibitors. 110 (34%) participants were female and 214 (66%) were male. A globally diverse population was included with 103 (32%) Asian, 23 (7%) Black or African American, and 183 (56%) White participants. Balcinrenone 15 mg plus dapagliflozin 10 mg and balcinrenone 40 mg plus dapagliflozin 10 mg were superior in reducing UACR versus dapagliflozin 10 mg plus placebo throughout the treatment period. At week 12, the UACR difference versus dapagliflozin 10 mg plus placebo was -22·8% (90% CI -33·3 to -10·7; p=0·0038) for balcinrenone 15 mg plus dapagliflozin 10 mg and -32·8% (-42·0 to -22·1; p<0·0001) for balcinrenone 40 mg plus dapagliflozin 10 mg. Investigator-reported adverse events of hyperkalaemia were reported in 6% (seven of 108) of the balcinrenone 15 mg plus dapagliflozin 10 mg group, 7% (eight of 110) of the balcinrenone 40 mg plus dapagliflozin 10 mg group, and 5% (five of 106) of the dapagliflozin 10 mg plus placebo group. Adverse events of hypotension and renal events were few, balanced across the treatment groups, and none were serious. Two deaths occurred during the study, both more than 28 days after the last dose of study drug. INTERPRETATION: In participants with chronic kidney disease at increased risk of disease progression, a fixed dose combination of balcinrenone and dapagliflozin was superior to dapagliflozin alone in reducing albuminuria. Balcinrenone plus dapagliflozin was well tolerated, effects on potassium were minor, and no unexpected safety concerns were identified. FUNDING: AstraZeneca.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Cardona JF, Jolly S, et al. Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial. Lancet. 2025. PMID: 41218621. doi:10.1016/S0140-6736(25)02014-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。